Documentation-first vendor qualification
Pain management and physical medicine practices that add a new regenerative biologics line typically start by reviewing donor eligibility screening, processing timelines, and sterility testing results for a specific lot rather than placing a trial order first. In a multi-physician practice, this review is often centralized through a medical director.
Precision Biologics supports that review with lot-specific certificates of analysis, donor eligibility summaries, and lot release records, available to any verified account on request.
New Orleans
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
123- Pain Medicine
- 45
- Physical Medicine & Rehabilitation
- 78
NPI verification
Accounts are opened only after NPI verification through the NPPES registry. This keeps ordering authority tied to a licensed physician's record, which matters for group practices coordinating purchasing across multiple providers.
Cold chain and shelf-stable formats
Cryopreserved Wharton's jelly products ship overnight on dry ice in validated containers and are stored at -80 degrees C on arrival, so a practice should plan for a receiving step that logs temperature and lot number. The lyophilized Wharton's jelly format and the lyophilized exosome products are shelf-stable and do not require that cold-chain handling, giving a practice more flexibility in storage planning.
Regulatory posture and onboarding support
FDA has stated there is no FDA-approved exosome product, and exosome products in this category are generally regulated as biologic drugs; decisions about their purchase and use rest with the ordering physician and their regulatory counsel. For Wharton's jelly products, whether an intended use meets the minimal-manipulation and homologous-use criteria of 21 CFR 1271.10 is a determination for the practice and its own counsel. A practice should also verify its physicians' standing directly with the Louisiana medical board.
Precision Biologics supports new accounts with NPI-based verification and physician-level calls focused on product documentation, not clinical guidance.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Can our practice centralize purchasing across several physicians?+
Each account is tied to a verified NPI number, so a practice can either designate one physician's account for group purchasing or open separate accounts per physician.
Is there a minimum order requirement for a new account?+
Order details, including any minimums, are discussed with verified accounts directly. Pricing and ordering terms are not published and are shared after NPI verification.
Does Precision Biologics advise on dosing or injection protocols?+
No. Precision Biologics provides product documentation only. Dosing, protocol, and intended-use decisions belong to the ordering physician and their regulatory counsel.